Topical Application of AS101 for the Treatment of Psoriasis

Mild to Moderate Psoriasis Clinical Trial

Official title:
Study of Topical Application of AS101 for the Treatment of Psoriasis

Status Withdrawn

Clinical Trial Summary

This protocol relates to a phase II randomized double blind, placebo controlled study of the AS101 topical application for the treatment of mild to moderate Psoriasis.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00788424
Study type	Interventional
Source	BioMAS Ltd
Contact
Status	Withdrawn
Phase	Phase 2
Start date	November 2008
Completion date	February 2010

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03222622` - Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis	Phase 2
Completed	`NCT02529956` - A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis	Phase 1
Completed	`NCT01587755` - Optimising Outpatient Care in Mild to Moderate Psoriasis (PSO-TOP)	Phase 4
Recruiting	`NCT05249972` - A Phase III Study in Subjects With Mild to Moderate Psoriasis.	Phase 3
Recruiting	`NCT05965089` - A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.	Phase 1
Completed	`NCT01000714` - Determination of the Efficacy and Safety of Psirelax in the Relief of the Disease in Psoriasis	Phase 2